amifostine anhydrous has been researched along with Ovarian Neoplasms in 32 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ninety ovarian cancer patients were randomized to receive standard paclitaxel + carboplatin without (PC) or preceded by amifostine 740 mg/m(2) (PC + A)." | 2.71 | A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. ( Boezen, HM; Bos, AM; de Graaf, H; de Swart, CA; De Vos, FY; de Vries, EG; Schaapveld, M; van der Zee, AG; Willemse, PH, 2005) |
| "Topotecan was given as a 30-min IV infusion." | 2.70 | No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. ( Malmström, H; Peterson, C; Zackrisson, AL, 2002) |
| "Twenty patients with advanced ovarian cancer were treated with chemotherapy PC (cisplatin 100 mg/m2, cyclophosphamide 1000 mg/m2) administered with amifostine." | 2.69 | [Evaluation of efficacy and toxicity of PC chemotherapy (cisplatin, cyclophosphamide) administered with amifostine in patients with clinically advanced ovarian cancer]. ( Pawlicki, M; Rolski, J; Rychlik, U; Wiczyńska, B, 1998) |
| "Amifostine (Ethyol) administered to cancer patients is rapidly cleared from plasma by a biphasic decay with an alpha half-life (T1/2 alpha) of 0." | 2.39 | Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo. ( Korst, AE; van der Vijgh, WJ, 1996) |
| " Our results confirm previous reports of the ability of amifostine to protect normal tissues from the toxic effects of chemotherapy drugs and now extend these observations to paclitaxel." | 1.30 | Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. ( Capizzi, RL; Fernandes, D; Johnson, CS; List, AF; Paine-Murrieta, GD; Taylor, CW; Wang, LM, 1997) |
| "For a model of advanced ovarian cancer, mice received tumor cell injections on day 0 and did not begin drug treatment until tumors were palpable (0." | 1.29 | Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results. ( Capizzi, RL; Johnson, CS; Lopez, MH; Paine, GD; Taylor, CW, 1996) |
| " Selectivity of protection by WR2721 is probably due to the preferential formation and uptake of the thiol metabolite 2-(3-aminopropylamino)ethanethiol (WR1065), which can inactivate toxic platinum-species inside the cell." | 1.28 | Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. ( Boven, E; Holwerda, U; Pinedo, HM; Treskes, M; van der Vijgh, WJ, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.13) | 18.7374 |
| 1990's | 22 (68.75) | 18.2507 |
| 2000's | 8 (25.00) | 29.6817 |
| 2010's | 1 (3.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouhadjari, N | 1 |
| Gabato, W | 1 |
| Calabrese, D | 1 |
| Msika, S | 1 |
| Keita, H | 1 |
| Berry, E | 1 |
| Matthews, KS | 1 |
| Singh, DK | 1 |
| Buttin, BM | 1 |
| Lurain, JR | 1 |
| Alvarez, RD | 1 |
| Schink, J | 1 |
| Lorusso, D | 1 |
| Ferrandina, G | 1 |
| Greggi, S | 1 |
| Gadducci, A | 1 |
| Pignata, S | 1 |
| Tateo, S | 1 |
| Biamonte, R | 1 |
| Manzione, L | 1 |
| Di Vagno, G | 1 |
| Ferrau', F | 1 |
| Scambia, G | 1 |
| De Vos, FY | 1 |
| Bos, AM | 1 |
| Schaapveld, M | 1 |
| de Swart, CA | 1 |
| de Graaf, H | 1 |
| van der Zee, AG | 1 |
| Boezen, HM | 1 |
| de Vries, EG | 1 |
| Willemse, PH | 1 |
| Hilpert, F | 1 |
| Stähle, A | 1 |
| Tomé, O | 1 |
| Burges, A | 1 |
| Rossner, D | 1 |
| Späthe, K | 1 |
| Heilmann, V | 1 |
| Richter, B | 1 |
| du Bois, A | 1 |
| Alberts, DS | 1 |
| Delforge, A | 1 |
| Capizzi, RL | 5 |
| Treskes, M | 2 |
| Boven, E | 5 |
| van de Loosdrecht, AA | 1 |
| Wijffels, JF | 1 |
| Cloos, J | 1 |
| Peters, GJ | 1 |
| Pinedo, HM | 3 |
| van der Vijgh, WJ | 6 |
| Kemp, G | 1 |
| Rose, P | 1 |
| Lurain, J | 1 |
| Berman, M | 1 |
| Manetta, A | 1 |
| Roullet, B | 1 |
| Homesley, H | 1 |
| Belpomme, D | 1 |
| Glick, J | 1 |
| Paine, GD | 1 |
| Taylor, CW | 2 |
| Lopez, MH | 1 |
| Johnson, CS | 2 |
| Rose, PG | 1 |
| Facchini, T | 1 |
| Korst, AE | 3 |
| van der Sterre, ML | 2 |
| Fichtinger-Schepman, AM | 2 |
| Wang, LM | 1 |
| List, AF | 1 |
| Fernandes, D | 1 |
| Paine-Murrieta, GD | 1 |
| Dranitsaris, G | 1 |
| Shapiro, JD | 1 |
| Rothenberg, ML | 1 |
| Sarosy, GA | 1 |
| Steinberg, SM | 1 |
| Adamo, DO | 1 |
| Reed, E | 1 |
| Ozols, RF | 1 |
| Kohn, EC | 1 |
| Pawlicki, M | 1 |
| Rolski, J | 1 |
| Wiczyńska, B | 1 |
| Rychlik, U | 1 |
| Longo, CJ | 1 |
| Lindemann, K | 1 |
| Garzetti, GG | 1 |
| Ciavattini, A | 1 |
| Muzzioli, M | 1 |
| Romanini, C | 1 |
| Calhoun, EA | 1 |
| Bennett, CL | 1 |
| Ng, TY | 1 |
| Ngan, HY | 1 |
| Cheng, DK | 1 |
| Wong, LC | 1 |
| Nagy, P | 1 |
| Kádasi, L | 1 |
| Verschraagen, M | 1 |
| Hulscher, TM | 1 |
| Erkelens, CA | 1 |
| Hausheer, FH | 1 |
| Zackrisson, AL | 1 |
| Malmström, H | 1 |
| Peterson, C | 1 |
| Hamers, F | 1 |
| Neijt, J | 1 |
| Gispen, W | 1 |
| Holwerda, U | 1 |
| Niibe, H | 1 |
| Takahashi, I | 1 |
| Miyaishi, K | 1 |
| Mitsuhashi, N | 1 |
| Maehara, Y | 1 |
| Nakajima, N | 1 |
| Suto, H | 1 |
| Saito, Y | 1 |
| Yamakawa, M | 1 |
| Sugiyama, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma[NCT00003322] | Phase 3 | 384 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for amifostine anhydrous and Ovarian Neoplasms
| Article | Year |
|---|---|
Maximizing the delivery of intraperitoneal therapy while minimizing drug toxicity and maintaining quality of life.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug-Related S | 2006 |
Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
Topics: Amifostine; Antineoplastic Agents; Cell Survival; Clinical Trials as Topic; Female; Humans; Male; Ne | 1994 |
Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
Topics: Amifostine; Animals; Antineoplastic Agents; Carboplatin; Cisplatin; DNA Adducts; Drug Administration | 1996 |
Clinical status and optimal use of amifostine.
Topics: Amifostine; Animals; Antineoplastic Agents; Bone Marrow Cells; Clinical Trials, Phase III as Topic; | 1999 |
Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Topics: Amifostine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1999 |
11 trials available for amifostine anhydrous and Ovarian Neoplasms
| Article | Year |
|---|---|
Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Erythrocyte Count; Female; Humans; Infu | 2003 |
A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free S | 2005 |
Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AG
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; | 2005 |
Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide | 1996 |
Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Cyclophosphamide | 1996 |
Advances in supportive therapy.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Female; Hum | 1996 |
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclo | 1998 |
[Evaluation of efficacy and toxicity of PC chemotherapy (cisplatin, cyclophosphamide) administered with amifostine in patients with clinically advanced ovarian cancer].
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide | 1998 |
Cisplatin-based polychemotherapy reduces the natural cytotoxicity of peripheral blood mononuclear cells in patients with advanced ovarian carcinoma and their in vitro responsiveness to interleukin-12 incubation.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma, Serous; C | 1999 |
No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Area Under Curve; Chromatography, High Pressure Liqu | 2002 |
[An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 2. Abdominal and pelvic tumors].
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Double-Blind Method; Fe | 1985 |
16 other studies available for amifostine anhydrous and Ovarian Neoplasms
| Article | Year |
|---|---|
Hyperthermic intraperitoneal chemotherapy with cisplatin: Amifostine prevents acute severe renal impairment.
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy P | 2016 |
An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2009 |
Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.
Topics: Amifostine; Animals; Bone Marrow; Carboplatin; Cell Division; Dose-Response Relationship, Drug; Drug | 1994 |
Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results.
Topics: Amifostine; Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Drug Therapy, Combin | 1996 |
Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
Topics: Amifostine; Animals; Antineoplastic Agents; Body Temperature; Carboplatin; DNA Adducts; Drug Adminis | 1997 |
Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.
Topics: Amifostine; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Culture | 1997 |
A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Agents; Attitude to Health; Canada; Cost Savings; Cost | 1997 |
Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice.
Topics: Amifostine; Animals; Antineoplastic Agents; Cisplatin; Drug Combinations; Drug Synergism; Female; Hu | 1998 |
Choices of methodology in pharmacoeconomics studies.
Topics: Amifostine; Antineoplastic Agents, Alkylating; Attitude of Health Personnel; Canada; Cisplatin; Cost | 1999 |
Administration of the cytoprotectant amifostine.
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Kidney | 1998 |
Pharmacoeconomics of amifostine in ovarian cancer.
Topics: Amifostine; Antineoplastic Agents; Canada; Cost-Benefit Analysis; Cytoprotection; Female; Humans; Mo | 1999 |
The effect of amifostine on the in vitro cytotoxicity of chemotherapeutic agents in three epithelial ovarian carcinoma cell lines.
Topics: Amifostine; Antineoplastic Agents; Carcinoma; Drug Interactions; Female; Humans; Ovarian Neoplasms; | 1999 |
[Cytoprotective effect of Amifostine in the combined chemotherapy of advanced ovarian carcinoma].
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; | 2000 |
BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
Topics: Amifostine; Animals; Antineoplastic Agents; Carboplatin; Cell Division; Cisplatin; Drug Interactions | 2002 |
Protection of cisplatin-induced neuropathy: recent developments.
Topics: Adrenocorticotropic Hormone; Amifostine; Anticonvulsants; Cisplatin; Female; Glutathione; Humans; Ne | 1992 |
Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
Topics: Amifostine; Animals; Cisplatin; Drug Administration Schedule; Female; Kidney; Liver; Male; Mannitol; | 1992 |